Netherlands· NL-a93cd63f8dc2
Vyepti 100 mg/ml, concentraat voor oplossing voor infusie
A eptinezumab product containing eptinezumab, registered in Netherlands by H. Lundbeck A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- EPTINEZUMAB
- Manufacturer
- H. Lundbeck A/S
- Country
- Netherlands (NL)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1599
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVYEPTIAbacus Medicine A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- SpainVYEPTI 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONH. Lundbeck A/S
- BelgiumVyepti 100 mgH. Lundbeck
- CanadaVYEPTILUNDBECK CANADA INC
- SwitzerlandVyepti 100 mg/1 ml, Konzentrat zur Herstellung einer InfusionslösungLundbeck (Schweiz) AG
- NorwayVyeptiH. Lundbeck A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vyepti
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/978a1688-ac80-429b-9c8a-c6fc42d17cc5 GET /v1/drugs/978a1688-ac80-429b-9c8a-c6fc42d17cc5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vyepti-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Eptinezumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127633",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLYSORBAAT 80 (E 433)",
"SORBITOL (E 420)",
"WATER VOOR INJECTIE"
],
"substances": [
"EPTINEZUMAB"
],
"leaflet_url": null,
"authorised_at": "2022/01/24",
"procedure_number": "EMEA/H/C/005287",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1599",
"additional_monitoring": "N"
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.